Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 29

1.

Knockdown of miR-128a induces Lin28a expression and reverts myeloid differentiation blockage in acute myeloid leukemia.

De Luca L, Trino S, Laurenzana I, Tagliaferri D, Falco G, Grieco V, Bianchino G, Nozza F, Campia V, D'Alessio F, La Rocca F, Caivano A, Villani O, Cilloni D, Musto P, Del Vecchio L.

Cell Death Dis. 2017 Jun 1;8(6):e2849. doi: 10.1038/cddis.2017.253.

PMID:
28569789
2.

Heavy/light chain ratio for the assessment of minimal residual disease in myeloma patients achieving complete response.

D'Auria F, La Rocca F, Simeon V, Statuto T, Pietrantuono G, D'Arena G, Villani O, Mansueto G, Traficante A, Musto P.

Br J Haematol. 2017 Apr 25. doi: 10.1111/bjh.14662. [Epub ahead of print] No abstract available.

PMID:
28439880
3.

Iron-chelating therapy with deferasirox in transfusion-dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre study.

Musto P, Maurillo L, Simeon V, Poloni A, Finelli C, Balleari E, Ricco A, Rivellini F, Cortelezzi A, Tarantini G, Villani O, Mansueto G, Milella MR, Scapicchio D, Marziano G, Breccia M, Niscola P, Sanna A, Clissa C, Voso MT, Fenu S, Venditti A, Santini V, Angelucci E, Levis A.

Br J Haematol. 2017 Jun;177(5):741-750. doi: 10.1111/bjh.14621. Epub 2017 Apr 17.

PMID:
28419408
4.

Epha3 acts as proangiogenic factor in multiple myeloma.

Caivano A, La Rocca F, Laurenzana I, Annese T, Tamma R, Famigliari U, Simeon V, Trino S, De Luca L, Villani O, Berardi S, Basile A, Vacca A, Saglio G, Del Vecchio L, Musto P, Cilloni D.

Oncotarget. 2017 May 23;8(21):34298-34309. doi: 10.18632/oncotarget.16100.

5.

MicroRNA-155 in serum-derived extracellular vesicles as a potential biomarker for hematologic malignancies - a short report.

Caivano A, La Rocca F, Simeon V, Girasole M, Dinarelli S, Laurenzana I, De Stradis A, De Luca L, Trino S, Traficante A, D'Arena G, Mansueto G, Villani O, Pietrantuono G, Laurenti L, Del Vecchio L, Musto P.

Cell Oncol (Dordr). 2017 Feb;40(1):97-103. doi: 10.1007/s13402-016-0300-x. Epub 2016 Oct 19.

PMID:
27761889
6.

Characterization and prognostic relevance of circulating microvesicles in chronic lymphocytic leukemia.

De Luca L, D'Arena G, Simeon V, Trino S, Laurenzana I, Caivano A, La Rocca F, Villani O, Mansueto G, Deaglio S, Innocenti I, Laurenti L, Molica S, Pietrantuono G, De Stradis A, Del Vecchio L, Musto P.

Leuk Lymphoma. 2017 Jun;58(6):1424-1432. doi: 10.1080/10428194.2016.1243790. Epub 2016 Oct 14.

PMID:
27739922
7.

A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma.

Larocca A, Bringhen S, Petrucci MT, Oliva S, Falcone AP, Caravita T, Villani O, Benevolo G, Liberati AM, Morabito F, Montefusco V, Passera R, De Rosa L, Omedé P, Vincelli ID, Spada S, Carella AM, Ponticelli E, Derudas D, Genuardi M, Guglielmelli T, Nozzoli C, Aghemo E, De Paoli L, Conticello C, Musolino C, Offidani M, Boccadoro M, Sonneveld P, Palumbo A.

Leukemia. 2016 Jun;30(6):1320-6. doi: 10.1038/leu.2016.36. Epub 2016 Feb 22.

8.

Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Gruppo Italiano Malattie EMatologiche dell'Adulto Multiple Myeloma Working Party study.

Musto P, Simeon V, Grossi A, Gay F, Bringhen S, Larocca A, Guariglia R, Pietrantuono G, Villani O, D'Arena G, Cuomo C, Musto C, Morabito F, Petrucci MT, Offidani M, Zamagni E, Tacchetti P, Conticello C, Milone G, Palumbo A, Cavo M, Boccadoro M.

Stem Cell Res Ther. 2015 Apr 17;6:64. doi: 10.1186/s13287-015-0033-1.

9.

Azacitidine frontline therapy for unfit acute myeloid leukemia patients: clinical use and outcome prediction.

Ramos F, Thépot S, Pleyer L, Maurillo L, Itzykson R, Bargay J, Stauder R, Venditti A, Seegers V, Martínez-Robles V, Burgstaller S, Récher C, Debén G, Gaidano G, Gardin C, Musto P, Greil R, Sánchez-Guijo F, Fenaux P; European ALMA Investigators.

Leuk Res. 2015 Mar;39(3):296-306. doi: 10.1016/j.leukres.2014.12.013. Epub 2014 Dec 31.

PMID:
25601157
10.

More on spontaneous regression of chronic lymphocytic leukemia: two new cases and potential role of lamivudine in a further patient with advanced disease and hepatitis B virus infection.

D'Arena G, Guariglia R, Pietrantuono G, Villani O, Martorelli MC, Mansueto G, Criscuolo C, Pierri T, Musto C, Musto P.

Leuk Lymphoma. 2014 Aug;55(8):1955-7. doi: 10.3109/10428194.2013.858151. Epub 2014 Feb 14. No abstract available.

PMID:
24152050
11.

Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia.

Musto P, Simeon V, Martorelli MC, Petrucci MT, Cascavilla N, Di Raimondo F, Caravita T, Morabito F, Offidani M, Olivieri A, Benevolo G, Mina R, Guariglia R, D'Arena G, Mansueto G, Filardi N, Nobile F, Levi A, Falcone A, Cavalli M, Pietrantuono G, Villani O, Bringhen S, Omedè P, Lerose R, Agnelli L, Todoerti K, Neri A, Boccadoro M, Palumbo A.

Leukemia. 2014 Jan;28(1):222-5. doi: 10.1038/leu.2013.241. Epub 2013 Aug 20. No abstract available.

PMID:
23958922
12.

No cross-resistance after sequential use of romiplostim and eltrombopag in chronic immune thrombocytopenic purpura.

D'Arena G, Guariglia R, Mansueto G, Martorelli MC, Pietrantuono G, Villani O, Lerose R, Musto P.

Blood. 2013 Feb 14;121(7):1240-2. doi: 10.1182/blood-2012-11-465575. No abstract available. Erratum in: Blood. 2014 Mar 20;123(12):1971. Dosage error in article text.

13.

An urologic face of chronic lymphocytic leukemia: sequential prostatic and penis localization.

D'Arena G, Guariglia R, Villani O, Martorelli MC, Pietrantuono G, Mansueto G, Patitucci G, Imbriani E, Masciandaro T, Borgia L, Vita G, D'Auria F, Statuto T, Musto P.

Mediterr J Hematol Infect Dis. 2013;5(1):e2013008. doi: 10.4084/MJHID.2013.008. Epub 2013 Jan 2.

14.

Cardiovascular events and intensity of treatment in polycythemia vera.

Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, De Stefano V, Elli E, Iurlo A, Latagliata R, Lunghi F, Lunghi M, Marfisi RM, Musto P, Masciulli A, Musolino C, Cascavilla N, Quarta G, Randi ML, Rapezzi D, Ruggeri M, Rumi E, Scortechini AR, Santini S, Scarano M, Siragusa S, Spadea A, Tieghi A, Angelucci E, Visani G, Vannucchi AM, Barbui T; CYTO-PV Collaborative Group.

N Engl J Med. 2013 Jan 3;368(1):22-33. doi: 10.1056/NEJMoa1208500. Epub 2012 Dec 8.

15.

Chronic lymphocytic leukemia after chronic myeloid leukemia in the same patient: two different genomic events and a common treatment?

D'Arena G, Gemei M, Luciano L, D'Auria F, Deaglio S, Statuto T, Bianchino G, Grieco V, Mansueto G, Guariglia R, Pietrantuono G, Martorelli MC, Villani O, Del Vecchio L, Musto P.

J Clin Oncol. 2012 Nov 10;30(32):e327-30. doi: 10.1200/JCO.2012.42.6767. Epub 2012 Sep 24. No abstract available.

PMID:
23008321
16.

Quality of life and physicians' perception in myelodysplastic syndromes.

Oliva EN, Finelli C, Santini V, Poloni A, Liso V, Cilloni D, Impera S, Terenzi A, Levis A, Cortelezzi A, Ghio R, Musto P, Semenzato G, Clissa C, Lunghi T, Trappolini S, Gaidano V, Salvi F, Reda G, Villani O, Binotto G, Cufari P, Cavalieri E, Spiriti MA.

Am J Blood Res. 2012;2(2):136-47. Epub 2012 May 25.

17.

A shorter time to the first treatment may be predicted by the absolute number of regulatory T-cells in patients with Rai stage 0 chronic lymphocytic leukemia.

D'Arena G, D'Auria F, Simeon V, Laurenti L, Deaglio S, Mansueto G, Del Principe MI, Statuto T, Pietrantuono G, Guariglia R, Innocenti I, Martorelli MC, Villani O, De Feo V, Del Poeta G, Musto P.

Am J Hematol. 2012 Jun;87(6):628-31. doi: 10.1002/ajh.23170. Epub 2012 Mar 28.

18.

Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party.

D'Arena G, Valentini CG, Pietrantuono G, Guariglia R, Martorelli MC, Mansueto G, Villani O, Onofrillo D, Falcone A, Specchia G, Semenzato G, Di Renzo N, Mastrullo L, Venditti A, Ferrara F, Palumbo A, Pagano L, Musto P.

Ann Oncol. 2012 Jun;23(6):1499-502. doi: 10.1093/annonc/mdr480. Epub 2011 Oct 29.

PMID:
22039089
19.

Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study.

D'Arena G, Gobbi PG, Broglia C, Sacchi S, Quarta G, Baldini L, Iannitto E, Falcone A, Guariglia R, Pietrantuono G, Villani O, Martorelli MC, Mansueto G, Sanpaolo G, Cascavilla N, Musto P; Gimema (Gruppo Italiano Malattie Ematologiche Dell'Adulto); Multiple Myeloma Working Party; Gisl (Gruppo Italiano Studio Linfomi) Cooperative Group.

Leuk Lymphoma. 2011 May;52(5):771-5. doi: 10.3109/10428194.2011.553000. Epub 2011 Feb 8.

PMID:
21299465
20.

Positive effects on hematopoiesis in patients with myelodysplastic syndrome receiving deferasirox as oral iron chelation therapy: a brief review.

Guariglia R, Martorelli MC, Villani O, Pietrantuono G, Mansueto G, D'Auria F, Grieco V, Bianchino G, Lerose R, Bochicchio GB, Musto P.

Leuk Res. 2011 May;35(5):566-70. doi: 10.1016/j.leukres.2010.11.027. Epub 2010 Dec 23. Review.

PMID:
21185078

Supplemental Content

Loading ...
Support Center